Telmisartan

Telmisartan is a long-acting blood-pressure medicine with large cardiovascular outcome trials. Its metabolic evidence is mixed: some small studies in insulin-resistant patients found benefits, while other trials were neutral. It has no established role as a fat-loss drug or protection against every cardiovascular effect of anabolic steroids.

Selective angiotensin II AT1-receptor blocker

US approval includes hypertension and a defined ACE-inhibitor-intolerant high-risk population.
ONTARGET established noninferiority to ramipril and showed that dual blockade added harm without benefit.
TRANSCEND and PRoFESS clarify important null boundaries.
Small insulin-resistant patient studies were positive, while other metabolic trials were neutral.

Is telmisartan just a blood-pressure drug?

Telmisartan is approved for hypertension. The US label also covers reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk adults aged 55 or older who cannot take ACE inhibitors. The EU record uses different prevention wording, so the jurisdiction and patient definition matter.

US label · hypertension and CV-risk reduction

FDA prescribing information

Alembic Pharmaceuticals Inc. TELMISARTAN tablets. DailyMed setid c62d424c-7630-413c-be2c-3932831c3f1d. Updated May 29, 2026.

The US label covers hypertension and reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk patients aged 55 or older unable to take ACE inhibitors. It describes selective AT1 blockade, roughly 24-hour terminal half-life, and fetal, renal, potassium, hypotension, dual-RAS, lithium, digoxin, and NSAID hazards.

Participants / model: Adults with hypertension; adults aged 55 or older at high cardiovascular risk who cannot take ACE inhibitors
Treatment: Oral telmisartan tablets
Follow-up: Current product record and supporting long-term outcome trials
Study design: Regulatory prescribing information

The cardiovascular-risk indication is narrower in the US than in the EU and does not imply a metabolic or weight-loss indication.

Read the original source

EMA · EU indications and authorization

European public assessment record

European Medicines Agency. Micardis (telmisartan), EPAR. European Union authorization July 16, 1998.

The EMA record identifies centralized EU authorization for essential hypertension and prevention of cardiovascular morbidity in defined high-risk adults.

Participants / model: Adults with essential hypertension or defined high cardiovascular risk
Treatment: Oral telmisartan
Follow-up: Current EPAR record
Study design: Regulatory product assessment

EU wording differs from the US ACE-inhibitor-intolerance condition; each jurisdiction's label applies separately.

Read the original source

PubChem CID 65999 · telmisartan identity

Government substance database

National Library of Medicine. PubChem Compound Summary for CID 65999, Telmisartan.

Identifies telmisartan as C33H30N4O2, molecular weight 514.6 g/mol, CID 65999.

Participants / model: Not applicable
Treatment: Not applicable
Follow-up: Living database record
Study design: Curated chemical identity record

Chemical identity does not establish an indication or prove PPAR-gamma-mediated clinical benefit.

Read the original source

What did ONTARGET establish, and what did it reject?

ONTARGET randomized 25,620 high-risk patients after a run-in and followed them for a median 56 months. The primary composite was 16.7% with telmisartan and 16.5% with ramipril (RR 1.01, 95% CI 0.94 to 1.09), meeting noninferiority. The combination was 16.3% and added no benefit. Compared with ramipril, telmisartan caused less cough (1.1% vs 4.2%) and angioedema (0.1% vs 0.3%) but more hypotensive symptoms (2.6% vs 1.7%); combining both raised hypotensive symptoms and renal dysfunction.

ONTARGET
Comparison	Primary outcome	Meaning
Telmisartan vs ramipril	16.7% vs 16.5%; RR 1.01, 95% CI 0.94 to 1.09	Noninferior; less cough and angioedema, more hypotensive symptoms
Combination vs ramipril	16.3% vs 16.5%; RR 0.99	No added benefit; hypotensive symptoms 4.8% and renal dysfunction 13.5%

ONTARGET · 25,620 high-risk patients

Randomized double-blind active-controlled outcome trial

ONTARGET Investigators; Salim Yusuf, Koon K. Teo, Janice Pogue, et al. New England Journal of Medicine. 2008. PMID 18378520.

Primary events occurred in 16.7% with telmisartan and 16.5% with ramipril (RR 1.01, 95% CI 0.94 to 1.09); combination therapy was 16.3% and added no benefit. Telmisartan caused less cough and angioedema but more hypotensive symptoms than ramipril; dual therapy increased hypotension and renal dysfunction.

Participants / model: 25,620 patients with vascular disease or high-risk diabetes without heart failure
Treatment: Telmisartan, ramipril, or both
Follow-up: Median follow-up 56 months
Study design: Randomized double-blind multicenter noninferiority and combination trial
Funding: Supported by Boehringer Ingelheim

Three-week run-in selected patients able to take study therapy. Results apply to high-risk vascular disease or diabetes without heart failure; they do not support dual blockade or healthy-person use.

Read the original source

US label · hypertension and CV-risk reduction

FDA prescribing information

Alembic Pharmaceuticals Inc. TELMISARTAN tablets. DailyMed setid c62d424c-7630-413c-be2c-3932831c3f1d. Updated May 29, 2026.

The US label covers hypertension and reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk patients aged 55 or older unable to take ACE inhibitors. It describes selective AT1 blockade, roughly 24-hour terminal half-life, and fetal, renal, potassium, hypotension, dual-RAS, lithium, digoxin, and NSAID hazards.

Participants / model: Adults with hypertension; adults aged 55 or older at high cardiovascular risk who cannot take ACE inhibitors
Treatment: Oral telmisartan tablets
Follow-up: Current product record and supporting long-term outcome trials
Study design: Regulatory prescribing information

The cardiovascular-risk indication is narrower in the US than in the EU and does not imply a metabolic or weight-loss indication.

Read the original source

Did every large cardiovascular trial come out positive?

TRANSCEND randomized 5,926 ACE-inhibitor-intolerant high-risk patients. Over a median 56 months, its primary composite was 15.7% with telmisartan and 17.0% with placebo (HR 0.92, 95% CI 0.81 to 1.05; p=0.216). A narrower composite reached p=0.048 before multiplicity adjustment and p=0.068 after it. PRoFESS randomized 20,332 recent-stroke patients: recurrent stroke was 8.7% versus 9.2% (HR 0.95; p=0.23), and major cardiovascular events were 13.5% versus 14.4%. Telmisartan discontinuation was higher in PRoFESS, led by hypotension.

Large trials that missed their primary target
Trial	Primary result	Adverse-event or design detail	Limit
TRANSCEND, n=5,926	15.7% vs 17.0%; HR 0.92 (0.81 to 1.05); p=0.216	Hypotensive symptoms 0.98% vs 0.54%	Secondary composite lost conventional significance after multiplicity adjustment
PRoFESS, n=20,332	Recurrent stroke 8.7% vs 9.2%; HR 0.95 (0.86 to 1.04); p=0.23	Discontinued 14.3% vs 11.1%; hypotension 3.9% vs 1.8%	Started median 15 days after stroke; mean follow-up 2.5 years; adherence declined

TRANSCEND · primary endpoint not significant

Randomized double-blind placebo-controlled outcome trial

TRANSCEND Investigators; S. Yusuf, K. Teo, C. Anderson, et al. The Lancet. 2008. PMID 18757085.

Primary events occurred in 15.7% with telmisartan and 17.0% with placebo (HR 0.92, 95% CI 0.81 to 1.05; p=0.216). The HOPE composite was 13.0% versus 14.8% (unadjusted p=0.048; multiplicity-adjusted p=0.068); mortality was 12.3% versus 11.7%.

Participants / model: 5,926 high-risk patients intolerant to ACE inhibitors
Treatment: Telmisartan versus placebo
Follow-up: Median 56 months
Study design: Randomized double-blind placebo-controlled multicenter trial
Funding: Boehringer Ingelheim

The primary endpoint was null. The narrower secondary result failed the prespecified multiplicity adjustment.

Read the original source

PRoFESS · 20,332 recent-stroke patients

Randomized double-blind placebo-controlled outcome trial

Salim Yusuf, Hans-Christoph Diener, Ralph L. Sacco, et al.; PRoFESS Study Group. New England Journal of Medicine. 2008. PMID 18753639.

Recurrent stroke occurred in 880/10,146 (8.7%) versus 934/10,186 (9.2%; HR 0.95, 95% CI 0.86 to 1.04; p=0.23). Major cardiovascular events were 13.5% versus 14.4%. Treatment stopped in 14.3% versus 11.1%, including hypotension in 3.9% versus 1.8%.

Participants / model: 20,332 patients recently experiencing ischemic stroke
Treatment: Telmisartan versus placebo
Follow-up: Mean follow-up 2.5 years
Study design: Randomized double-blind placebo-controlled multicenter trial
Funding: Boehringer Ingelheim

Treatment began a median 15 days after stroke, adherence declined, and placebo participants used somewhat more open-label blood-pressure therapy. The factorial design and 2.5-year mean follow-up constrain interpretation.

Read the original source

Does the PPAR-gamma effect improve insulin resistance or fat loss?

Some human metabolic trials are positive. The strongest broad conclusion is a possible benefit in certain insulin-resistant patients, with several null studies and no established healthy-person fat-loss effect.

In a blinded three-month comparison of 40 hypertensive patients with metabolic syndrome, HOMA-IR fell from about 5.7 to 4.24 with telmisartan versus 5.82 with losartan. Glucose and HbA1c also favored telmisartan. Blood-pressure control was better too, making a separate PPAR-gamma effect difficult to isolate. Fasting insulin did not meet the usual .05 threshold despite stronger abstract wording.

An eight-week comparison in 42 patients was neutral: baseline HOMA-IR was much lower, around 1.8 to 1.9. That difference in baseline impairment could matter, but it does not establish a responder rule. The larger 138-person overweight, nondiabetic study also failed its primary insulin-sensitivity comparison.

An open randomized 24-week study assigned 27 patients to telmisartan and 26 to amlodipine. CT-measured visceral fat and glucose-challenge measures improved with telmisartan; subcutaneous fat did not. The abstract does not report complete between-group estimates. A separate short study reported a within-arm HOMA-R improvement without BMI, HbA1c or lipid changes; that alone cannot establish superiority over its comparator.

Vitale et al., 40-person telmisartan versus losartan trial

Primary human study

Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular diabetology. 2005. DOI 10.1186/1475-2840-4-6.

Forty hypertensive patients with WHO-defined metabolic syndrome were randomized double-blind for three months. Baseline HOMA-IR was around 5.7. It fell to 4.24 with telmisartan versus 5.82 with losartan; fasting glucose and HbA1c also favored telmisartan. The fasting-insulin comparison was p<.06, despite stronger wording in the abstract. Blood-pressure control was better with telmisartan, complicating attribution to PPAR-gamma. Table labels/order and the prose describing correlations contain inconsistencies; precise numbers require care. No adverse events were reported, but 20-person arms cannot establish uncommon safety. Authors declared no competing interests.

Read the original source

Bahadir et al., 42-person neutral insulin-resistance trial

Randomized controlled human trial

Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertension research : official journal of the Japanese Society of Hypertension. 2007. DOI 10.1291/hypres.30.49.

Hypertensive metabolic-syndrome patients received telmisartan or losartan for eight weeks. HOMA-IR remained approximately 1.9 in the telmisartan arm and 1.8 in the losartan arm. Both lowered pressure similarly. These patients had much lower baseline HOMA-IR than Vitale's cohort, making baseline impairment a plausible effect modifier, not a proven responder rule. The negative result belongs beside the positive studies.

Study design: Randomized controlled trial; blinding and comparator details are stated in the source result.

Primary abstract and metadata

Read the original source

Shimabukuro et al., fat distribution in metabolic syndrome

Randomized controlled human trial

Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. Journal of hypertension. 2007. DOI 10.1097/hjh.0b013e3280287a83.

An open prospective randomized comparison assigned 27 patients to telmisartan and 26 to amlodipine for 24 weeks. Blood pressure fell comparably; CT-measured visceral fat area and oral-glucose-challenge measures improved in the telmisartan arm, while subcutaneous fat did not. This is a direct human body-composition signal. The abstract does not provide the full between-group estimates or adverse-event accounting; it cannot justify a quantified healthy-person fat-loss promise.

Study design: Randomized controlled trial; blinding and comparator details are stated in the source result.

The abstract does not report full numerical tables.

Read the original source

Ichikawa et al., telmisartan versus valsartan metabolic study

Randomized controlled human trial

Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Internal medicine (Tokyo, Japan). 2007. DOI 10.2169/internalmedicine.46.7173.

Over four weeks with lifestyle modification, telmisartan-arm HOMA-R fell from 3.11 to 2.56 (within-arm p=.031); BMI, HbA1c and lipids did not change. A significant result in one arm and a nonsignificant result in the other is not by itself a significant between-arm difference. The abstract lacks enough design detail to treat this as strong replication.

Study design: Randomized controlled trial; blinding and comparator details are stated in the source result.

Primary abstract and metadata

Read the original source

138 adults · metabolic surrogate trial null

Randomized placebo-controlled trial

Willa Hsueh, Giora Davidai, Robert Henry, and Sunder Mudaliar. Journal of Clinical Hypertension. 2010. PMID 20883237.

Of 138 randomized and treated, 128 completed. The prespecified per-protocol insulin-sensitivity analysis included 48 placebo and 42 telmisartan participants; adjusted change was 0.30 versus 0.19, between-group −0.11 (p=0.8217). Glucose, lipids, inflammatory markers, and the clamp subset were null.

Participants / model: 138 overweight or obese adults with metabolic-syndrome features but without hypertension or diabetes
Treatment: Telmisartan versus placebo
Follow-up: 16 weeks
Study design: Randomized placebo-controlled trial
Funding: Supported by Boehringer Ingelheim Pharmaceuticals

Participants were not selected for laboratory-confirmed insulin resistance. The primary analysis was per protocol, the clamp subgroup was smaller, follow-up lasted 16 weeks, and the sponsor supported the trial.

Read the original source

Cells and rats · PPAR-gamma hypothesis

Preclinical cell and animal study

Stephen C. Benson, Harrihar A. Pershadsingh, Christopher I. Ho, et al. Hypertension. 2004. PMID 15007034.

Telmisartan showed partial PPAR-gamma agonism in experimental systems, changed target-gene expression, and lowered glucose, insulin, and triglycerides in high-fat/high-carbohydrate-fed rats.

Participants / model: Cell systems and diet-challenged rats
Treatment: Telmisartan and other angiotensin-receptor blockers
Follow-up: Preclinical experimental exposure
Study design: Cellular assays and controlled rat experiment

The PPAR-gamma signal is mechanistic and preclinical. It cannot override the null 16-week human insulin-sensitivity trial.

Read the original source

Does the Chinese diabetic-nephropathy study prove kidney protection?

The native and publisher-translated abstracts describe 85 patients randomized to telmisartan or nitrendipine for 12 weeks, both with insulin. Blood pressure fell in both groups, while albumin excretion, cystatin C, hsCRP, and lipid changes favored telmisartan. The abstract reports no kidney-failure endpoint.

Chinese abstract · early diabetic nephropathy

Chinese randomized clinical study

冯琼, 冉建民, 劳干诚, 王慧, 张扬, 刘薇. 广州医学院学报. 2008;(1):32 to 35.

The publisher's Chinese and translated English abstracts report 85 patients randomized to telmisartan (45) or nitrendipine (40), both with insulin, for 12 weeks. Both lowered blood pressure; urinary albumin excretion, lipids, hsCRP, and cystatin C surrogate changes favored telmisartan.

Participants / model: 85 patients with early diabetic nephropathy
Treatment: Telmisartan plus insulin versus nitrendipine plus insulin
Follow-up: 12 weeks
Study design: Randomized comparative clinical study described in the abstract

Short surrogate outcomes cannot establish renal-failure or cardiovascular benefit.

Read the original source

Does the Russian older-adult comparison establish superiority?

This was a one-center observational comparison with 20 people per treatment group and physician-selected therapy described as pseudorandomization. Target blood pressure favored telmisartan in the overall four-group test, but the telmisartan-versus-olmesartan comparison was p=0.07, and publication assistance came from Unipharm.

Russian observational comparison · 80 patients

Russian prospective observational study

N. A. Mironov, S. A. Zakharchuk, A. G. Plisyuk, and Ya. A. Orlova. Атм сферA. Новости кардиологии. 2025;(2):31 to 36. DOI 10.24412/2076-4189-2025-13324.

In one center, 80 patients older than 60 were followed after physicians selected one of four antihypertensives. Target blood pressure at three months was reported in 85% for telmisartan, 75% olmesartan, 65% losartan, and 60% fosinopril; the overall comparison was p=0.044, while telmisartan versus olmesartan was p=0.07.

Participants / model: 80 patients older than 60, 20 per physician-selected treatment group
Treatment: Telmisartan, olmesartan, losartan, or fosinopril
Follow-up: 3 months
Study design: Prospective single-center observational comparison with author-described pseudorandomization
Funding: Publication assistance acknowledged from Unipharm

Treatment was not truly randomized, each group had 20 participants, follow-up was short, outcomes were blood-pressure targets, and the paper acknowledges publication assistance from Unipharm.

Read the original source

Why does telmisartan support once-daily clinical use without being metabolically simple?

The label reports peaks around 0.5 to 1 hour and an approximately 24-hour terminal half-life. More than 99.5 percent is protein bound, elimination is mainly biliary and fecal as unchanged drug, and the main glucuronide is inactive. Food, dose, and liver function change exposure.

US label · hypertension and CV-risk reduction

FDA prescribing information

Alembic Pharmaceuticals Inc. TELMISARTAN tablets. DailyMed setid c62d424c-7630-413c-be2c-3932831c3f1d. Updated May 29, 2026.

The US label covers hypertension and reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk patients aged 55 or older unable to take ACE inhibitors. It describes selective AT1 blockade, roughly 24-hour terminal half-life, and fetal, renal, potassium, hypotension, dual-RAS, lithium, digoxin, and NSAID hazards.

Participants / model: Adults with hypertension; adults aged 55 or older at high cardiovascular risk who cannot take ACE inhibitors
Treatment: Oral telmisartan tablets
Follow-up: Current product record and supporting long-term outcome trials
Study design: Regulatory prescribing information

The cardiovascular-risk indication is narrower in the US than in the EU and does not imply a metabolic or weight-loss indication.

Read the original source

Which interactions matter more than the wellness framing suggests?

Pregnancy exposure can injure or kill the fetus. Hypotension, hyperkalemia, and renal impairment matter, especially with volume depletion or kidney disease. Dual renin-angiotensin blockade generally adds harm without benefit; NSAIDs can blunt effect and worsen renal function; lithium toxicity can increase; and digoxin concentrations can rise.

US label · hypertension and CV-risk reduction

FDA prescribing information

Alembic Pharmaceuticals Inc. TELMISARTAN tablets. DailyMed setid c62d424c-7630-413c-be2c-3932831c3f1d. Updated May 29, 2026.

The US label covers hypertension and reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk patients aged 55 or older unable to take ACE inhibitors. It describes selective AT1 blockade, roughly 24-hour terminal half-life, and fetal, renal, potassium, hypotension, dual-RAS, lithium, digoxin, and NSAID hazards.

Participants / model: Adults with hypertension; adults aged 55 or older at high cardiovascular risk who cannot take ACE inhibitors
Treatment: Oral telmisartan tablets
Follow-up: Current product record and supporting long-term outcome trials
Study design: Regulatory prescribing information

The cardiovascular-risk indication is narrower in the US than in the EU and does not imply a metabolic or weight-loss indication.

Read the original source

ONTARGET · 25,620 high-risk patients

Randomized double-blind active-controlled outcome trial

ONTARGET Investigators; Salim Yusuf, Koon K. Teo, Janice Pogue, et al. New England Journal of Medicine. 2008. PMID 18378520.

Primary events occurred in 16.7% with telmisartan and 16.5% with ramipril (RR 1.01, 95% CI 0.94 to 1.09); combination therapy was 16.3% and added no benefit. Telmisartan caused less cough and angioedema but more hypotensive symptoms than ramipril; dual therapy increased hypotension and renal dysfunction.

Participants / model: 25,620 patients with vascular disease or high-risk diabetes without heart failure
Treatment: Telmisartan, ramipril, or both
Follow-up: Median follow-up 56 months
Study design: Randomized double-blind multicenter noninferiority and combination trial
Funding: Supported by Boehringer Ingelheim

Three-week run-in selected patients able to take study therapy. Results apply to high-risk vascular disease or diabetes without heart failure; they do not support dual blockade or healthy-person use.

Read the original source

Does it protect you during anabolic-steroid use?

Treating elevated blood pressure addresses a real risk. No controlled trial in the cited evidence establishes that telmisartan neutralizes the other cardiovascular consequences of anabolic-steroid use.

An AT1 blocker cannot be credited with preventing every change in cardiac structure, lipids, clotting or rhythm because it lowers a blood-pressure reading. ONTARGET also showed that combining telmisartan with ramipril added harm without improving outcomes. Hypotension, hyperkalemia and renal-function changes still matter, especially when baseline blood pressure is normal.

ONTARGET · 25,620 high-risk patients

Randomized double-blind active-controlled outcome trial

ONTARGET Investigators; Salim Yusuf, Koon K. Teo, Janice Pogue, et al. New England Journal of Medicine. 2008. PMID 18378520.

Primary events occurred in 16.7% with telmisartan and 16.5% with ramipril (RR 1.01, 95% CI 0.94 to 1.09); combination therapy was 16.3% and added no benefit. Telmisartan caused less cough and angioedema but more hypotensive symptoms than ramipril; dual therapy increased hypotension and renal dysfunction.

Participants / model: 25,620 patients with vascular disease or high-risk diabetes without heart failure
Treatment: Telmisartan, ramipril, or both
Follow-up: Median follow-up 56 months
Study design: Randomized double-blind multicenter noninferiority and combination trial
Funding: Supported by Boehringer Ingelheim

Three-week run-in selected patients able to take study therapy. Results apply to high-risk vascular disease or diabetes without heart failure; they do not support dual blockade or healthy-person use.

Read the original source

US label · hypertension and CV-risk reduction

FDA prescribing information

Alembic Pharmaceuticals Inc. TELMISARTAN tablets. DailyMed setid c62d424c-7630-413c-be2c-3932831c3f1d. Updated May 29, 2026.

The US label covers hypertension and reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk patients aged 55 or older unable to take ACE inhibitors. It describes selective AT1 blockade, roughly 24-hour terminal half-life, and fetal, renal, potassium, hypotension, dual-RAS, lithium, digoxin, and NSAID hazards.

Participants / model: Adults with hypertension; adults aged 55 or older at high cardiovascular risk who cannot take ACE inhibitors
Treatment: Oral telmisartan tablets
Follow-up: Current product record and supporting long-term outcome trials
Study design: Regulatory prescribing information

The cardiovascular-risk indication is narrower in the US than in the EU and does not imply a metabolic or weight-loss indication.

Read the original source

Studies and sources

US label · hypertension and CV-risk reduction

FDA prescribing information

Alembic Pharmaceuticals Inc. TELMISARTAN tablets. DailyMed setid c62d424c-7630-413c-be2c-3932831c3f1d. Updated May 29, 2026.

The US label covers hypertension and reduction of myocardial-infarction, stroke, or cardiovascular-death risk in high-risk patients aged 55 or older unable to take ACE inhibitors. It describes selective AT1 blockade, roughly 24-hour terminal half-life, and fetal, renal, potassium, hypotension, dual-RAS, lithium, digoxin, and NSAID hazards.

Participants / model: Adults with hypertension; adults aged 55 or older at high cardiovascular risk who cannot take ACE inhibitors
Treatment: Oral telmisartan tablets
Follow-up: Current product record and supporting long-term outcome trials
Study design: Regulatory prescribing information

The cardiovascular-risk indication is narrower in the US than in the EU and does not imply a metabolic or weight-loss indication.

Read the original source

EMA · EU indications and authorization

European public assessment record

European Medicines Agency. Micardis (telmisartan), EPAR. European Union authorization July 16, 1998.

The EMA record identifies centralized EU authorization for essential hypertension and prevention of cardiovascular morbidity in defined high-risk adults.

Participants / model: Adults with essential hypertension or defined high cardiovascular risk
Treatment: Oral telmisartan
Follow-up: Current EPAR record
Study design: Regulatory product assessment

EU wording differs from the US ACE-inhibitor-intolerance condition; each jurisdiction's label applies separately.

Read the original source

ONTARGET · 25,620 high-risk patients

Randomized double-blind active-controlled outcome trial

ONTARGET Investigators; Salim Yusuf, Koon K. Teo, Janice Pogue, et al. New England Journal of Medicine. 2008. PMID 18378520.

Primary events occurred in 16.7% with telmisartan and 16.5% with ramipril (RR 1.01, 95% CI 0.94 to 1.09); combination therapy was 16.3% and added no benefit. Telmisartan caused less cough and angioedema but more hypotensive symptoms than ramipril; dual therapy increased hypotension and renal dysfunction.

Participants / model: 25,620 patients with vascular disease or high-risk diabetes without heart failure
Treatment: Telmisartan, ramipril, or both
Follow-up: Median follow-up 56 months
Study design: Randomized double-blind multicenter noninferiority and combination trial
Funding: Supported by Boehringer Ingelheim

Three-week run-in selected patients able to take study therapy. Results apply to high-risk vascular disease or diabetes without heart failure; they do not support dual blockade or healthy-person use.

Read the original source

TRANSCEND · primary endpoint not significant

Randomized double-blind placebo-controlled outcome trial

TRANSCEND Investigators; S. Yusuf, K. Teo, C. Anderson, et al. The Lancet. 2008. PMID 18757085.

Primary events occurred in 15.7% with telmisartan and 17.0% with placebo (HR 0.92, 95% CI 0.81 to 1.05; p=0.216). The HOPE composite was 13.0% versus 14.8% (unadjusted p=0.048; multiplicity-adjusted p=0.068); mortality was 12.3% versus 11.7%.

Participants / model: 5,926 high-risk patients intolerant to ACE inhibitors
Treatment: Telmisartan versus placebo
Follow-up: Median 56 months
Study design: Randomized double-blind placebo-controlled multicenter trial
Funding: Boehringer Ingelheim

The primary endpoint was null. The narrower secondary result failed the prespecified multiplicity adjustment.

Read the original source

PRoFESS · 20,332 recent-stroke patients

Randomized double-blind placebo-controlled outcome trial

Salim Yusuf, Hans-Christoph Diener, Ralph L. Sacco, et al.; PRoFESS Study Group. New England Journal of Medicine. 2008. PMID 18753639.

Recurrent stroke occurred in 880/10,146 (8.7%) versus 934/10,186 (9.2%; HR 0.95, 95% CI 0.86 to 1.04; p=0.23). Major cardiovascular events were 13.5% versus 14.4%. Treatment stopped in 14.3% versus 11.1%, including hypotension in 3.9% versus 1.8%.

Participants / model: 20,332 patients recently experiencing ischemic stroke
Treatment: Telmisartan versus placebo
Follow-up: Mean follow-up 2.5 years
Study design: Randomized double-blind placebo-controlled multicenter trial
Funding: Boehringer Ingelheim

Treatment began a median 15 days after stroke, adherence declined, and placebo participants used somewhat more open-label blood-pressure therapy. The factorial design and 2.5-year mean follow-up constrain interpretation.

Read the original source

138 adults · metabolic surrogate trial null

Randomized placebo-controlled trial

Willa Hsueh, Giora Davidai, Robert Henry, and Sunder Mudaliar. Journal of Clinical Hypertension. 2010. PMID 20883237.

Of 138 randomized and treated, 128 completed. The prespecified per-protocol insulin-sensitivity analysis included 48 placebo and 42 telmisartan participants; adjusted change was 0.30 versus 0.19, between-group −0.11 (p=0.8217). Glucose, lipids, inflammatory markers, and the clamp subset were null.

Participants / model: 138 overweight or obese adults with metabolic-syndrome features but without hypertension or diabetes
Treatment: Telmisartan versus placebo
Follow-up: 16 weeks
Study design: Randomized placebo-controlled trial
Funding: Supported by Boehringer Ingelheim Pharmaceuticals

Participants were not selected for laboratory-confirmed insulin resistance. The primary analysis was per protocol, the clamp subgroup was smaller, follow-up lasted 16 weeks, and the sponsor supported the trial.

Read the original source

Cells and rats · PPAR-gamma hypothesis

Preclinical cell and animal study

Stephen C. Benson, Harrihar A. Pershadsingh, Christopher I. Ho, et al. Hypertension. 2004. PMID 15007034.

Telmisartan showed partial PPAR-gamma agonism in experimental systems, changed target-gene expression, and lowered glucose, insulin, and triglycerides in high-fat/high-carbohydrate-fed rats.

Participants / model: Cell systems and diet-challenged rats
Treatment: Telmisartan and other angiotensin-receptor blockers
Follow-up: Preclinical experimental exposure
Study design: Cellular assays and controlled rat experiment

The PPAR-gamma signal is mechanistic and preclinical. It cannot override the null 16-week human insulin-sensitivity trial.

Read the original source

Chinese abstract · early diabetic nephropathy

Chinese randomized clinical study

冯琼, 冉建民, 劳干诚, 王慧, 张扬, 刘薇. 广州医学院学报. 2008;(1):32 to 35.

The publisher's Chinese and translated English abstracts report 85 patients randomized to telmisartan (45) or nitrendipine (40), both with insulin, for 12 weeks. Both lowered blood pressure; urinary albumin excretion, lipids, hsCRP, and cystatin C surrogate changes favored telmisartan.

Participants / model: 85 patients with early diabetic nephropathy
Treatment: Telmisartan plus insulin versus nitrendipine plus insulin
Follow-up: 12 weeks
Study design: Randomized comparative clinical study described in the abstract

Short surrogate outcomes cannot establish renal-failure or cardiovascular benefit.

Read the original source

Russian observational comparison · 80 patients

Russian prospective observational study

N. A. Mironov, S. A. Zakharchuk, A. G. Plisyuk, and Ya. A. Orlova. Атм сферA. Новости кардиологии. 2025;(2):31 to 36. DOI 10.24412/2076-4189-2025-13324.

In one center, 80 patients older than 60 were followed after physicians selected one of four antihypertensives. Target blood pressure at three months was reported in 85% for telmisartan, 75% olmesartan, 65% losartan, and 60% fosinopril; the overall comparison was p=0.044, while telmisartan versus olmesartan was p=0.07.

Participants / model: 80 patients older than 60, 20 per physician-selected treatment group
Treatment: Telmisartan, olmesartan, losartan, or fosinopril
Follow-up: 3 months
Study design: Prospective single-center observational comparison with author-described pseudorandomization
Funding: Publication assistance acknowledged from Unipharm

Treatment was not truly randomized, each group had 20 participants, follow-up was short, outcomes were blood-pressure targets, and the paper acknowledges publication assistance from Unipharm.

Read the original source

PubChem CID 65999 · telmisartan identity

Government substance database

National Library of Medicine. PubChem Compound Summary for CID 65999, Telmisartan.

Identifies telmisartan as C33H30N4O2, molecular weight 514.6 g/mol, CID 65999.

Participants / model: Not applicable
Treatment: Not applicable
Follow-up: Living database record
Study design: Curated chemical identity record

Chemical identity does not establish an indication or prove PPAR-gamma-mediated clinical benefit.

Read the original source

Vitale et al., 40-person telmisartan versus losartan trial

Primary human study

Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular diabetology. 2005. DOI 10.1186/1475-2840-4-6.

Forty hypertensive patients with WHO-defined metabolic syndrome were randomized double-blind for three months. Baseline HOMA-IR was around 5.7. It fell to 4.24 with telmisartan versus 5.82 with losartan; fasting glucose and HbA1c also favored telmisartan. The fasting-insulin comparison was p<.06, despite stronger wording in the abstract. Blood-pressure control was better with telmisartan, complicating attribution to PPAR-gamma. Table labels/order and the prose describing correlations contain inconsistencies; precise numbers require care. No adverse events were reported, but 20-person arms cannot establish uncommon safety. Authors declared no competing interests.

Read the original source

Bahadir et al., 42-person neutral insulin-resistance trial

Randomized controlled human trial

Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertension research : official journal of the Japanese Society of Hypertension. 2007. DOI 10.1291/hypres.30.49.

Hypertensive metabolic-syndrome patients received telmisartan or losartan for eight weeks. HOMA-IR remained approximately 1.9 in the telmisartan arm and 1.8 in the losartan arm. Both lowered pressure similarly. These patients had much lower baseline HOMA-IR than Vitale's cohort, making baseline impairment a plausible effect modifier, not a proven responder rule. The negative result belongs beside the positive studies.

Study design: Randomized controlled trial; blinding and comparator details are stated in the source result.

Primary abstract and metadata

Read the original source

Shimabukuro et al., fat distribution in metabolic syndrome

Randomized controlled human trial

Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. Journal of hypertension. 2007. DOI 10.1097/hjh.0b013e3280287a83.

An open prospective randomized comparison assigned 27 patients to telmisartan and 26 to amlodipine for 24 weeks. Blood pressure fell comparably; CT-measured visceral fat area and oral-glucose-challenge measures improved in the telmisartan arm, while subcutaneous fat did not. This is a direct human body-composition signal. The abstract does not provide the full between-group estimates or adverse-event accounting; it cannot justify a quantified healthy-person fat-loss promise.

Study design: Randomized controlled trial; blinding and comparator details are stated in the source result.

The abstract does not report full numerical tables.

Read the original source

Ichikawa et al., telmisartan versus valsartan metabolic study

Randomized controlled human trial

Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Internal medicine (Tokyo, Japan). 2007. DOI 10.2169/internalmedicine.46.7173.

Over four weeks with lifestyle modification, telmisartan-arm HOMA-R fell from 3.11 to 2.56 (within-arm p=.031); BMI, HbA1c and lipids did not change. A significant result in one arm and a nonsignificant result in the other is not by itself a significant between-arm difference. The abstract lacks enough design detail to treat this as strong replication.

Study design: Randomized controlled trial; blinding and comparator details are stated in the source result.

Primary abstract and metadata

Read the original source

Why is Telmisartan in S tier?

S for blood-pressure treatment and its cardiovascular evidence. Small metabolic trials conflict, and the visceral-fat signal comes from patients with metabolic syndrome. Healthy-person recomp and protection during anabolic-steroid use remain unproved.